Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proof-of-Concept, Obs Study to Evaluate Accuracy of MetriDx Lab Developed Test (LDT) to Accurately Identify Endometriosis-specific Biological Markers Using Micro-fluidic Analysis of Cells Enabling Clinicians to Diagnose Endometriosis

NCT05698212 is registered in ClinicalTrials.gov with Hera Biotech, Inc. as lead sponsor.

NCT NCT05698212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05698212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proof-of-Concept, Obs Study to Evaluate Accuracy of MetriDx Lab Developed Test (LDT) to Accurately Identify Endometriosis-specific Biological Markers Using Micro-fluidic Analysis of Cells Enabling Clinicians to Diagnose Endometriosis
Lead sponsor
Hera Biotech, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
September 14, 2022
Completion date
April 10, 2023
Enrollment
75 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diagnosis, endometriosis